Lost and Foundayo: Should You Switch to the GLP-1 Pill?
By Dr. Clete Barrick, MD | Board-Certified Internal Medicine & Obesity Medicine
This is my full Foundayo review as a physician who prescribes GLP-1 medications daily and takes tirzepatide himself. The FDA just approved Foundayo (orforglipron), the first GLP-1 pill you can take any time of day with no fasting, no water rules, and no needles. It is a once-daily tablet for adults with obesity (or overweight with at least one weight-related condition), and the approval happened in 50 days, the fastest for a new molecular entity since 2002.
In the ATTAIN-1 trial, patients on the highest dose lost an average of 12.4% of their body weight over 72 weeks. That is less than injectable tirzepatide or semaglutide. It is also the first oral GLP-1 that does not require you to take it on an empty stomach, wait 30 minutes, or restrict your water intake. Those two facts sit in tension, and how you weigh them depends entirely on your situation.
I take tirzepatide. I prescribe GLP-1 medications daily. I am not switching to Foundayo. But I am already prescribing it to certain patients, because for the right person, this pill fills a gap that injectables cannot. Here is everything you need to know.
Foundayo Review: What Makes It Different
Every injectable GLP-1 on the market right now is a peptide. Peptides are large, fragile proteins. Your stomach acid destroys them. That is why semaglutide and tirzepatide come as injections.
The Wegovy pill gets around this with a special absorption enhancer that protects the peptide through your stomach, but it comes with rules: empty stomach, small sip of water, wait 30 minutes before eating or drinking anything.
Foundayo is different. It is a small molecule, not a peptide. Think of it like most pills in your medicine cabinet. It survives your digestive system on its own. No protection needed. No fasting required. Take it with breakfast, at lunch, before bed. With coffee, with food, with whatever you want.
It activates the same GLP-1 receptor as semaglutide. The target is the same. The key to the lock is a different shape.
The Weight Loss Data (ATTAIN-1 Trial)
The ATTAIN-1 trial enrolled 3,127 adults with obesity and no diabetes across nine countries. Seventy-two weeks. Three dose groups plus placebo. Published in the New England Journal of Medicine.
At the highest dose, patients who stayed on treatment lost an average of 12.4% of their body weight. About 27 pounds. Across all patients regardless of whether they completed the trial, 11.1%. About 25 pounds.
Let me be direct. That is less than injectable tirzepatide and less than injectable semaglutide. Zepbound trials showed around 22% weight loss. Wegovy injection around 15 to 17%. The Wegovy pill around 17%. Foundayo at 12.4% is not in that tier.
But the comparison is not that simple. Different trials, different populations, different timeframes. And the trial also showed improvements in waist circumference, blood pressure, triglycerides, non-HDL cholesterol, and hsCRP. This is not just a weight loss drug. It is improving cardiometabolic markers across the board.
| Medication | Type | Route | Avg Weight Loss | Frequency | Food/Water Rules |
|---|---|---|---|---|---|
| Foundayo (orforglipron) | Small molecule | Daily pill | ~12% | Once daily | None |
| Wegovy pill (semaglutide) | Peptide | Daily pill | ~17% | Once daily | Empty stomach, 30-min fast |
| Wegovy injection (semaglutide) | Peptide | Weekly shot | ~15-17% | Once weekly | N/A |
| Zepbound (tirzepatide) | Peptide (dual GIP/GLP-1) | Weekly shot | ~22% | Once weekly | N/A |
Cross-trial comparisons have limitations. These drugs were not tested head-to-head in the same obesity study (except SURMOUNT-5 for semaglutide vs. tirzepatide injections).
Dosing: Six Strengths and the 7-Day Restart Rule
Foundayo comes in six dose strengths, each color-coded to reduce pharmacy errors. You start at 0.8 mg. Every 30 days, your dose can increase: 2.5 mg, then 5.5, then 9, then 14.5, then 17.2 mg at the top.
That is five possible increases over a minimum of five months to reach the maximum dose. Compare that to tirzepatide or semaglutide, which have four steps. More steps means more room to find the dose that works for you without jumping too far.
| Step | Dose | Tablet Color | Monthly Cost (Self-Pay) | Min. Time at Dose |
|---|---|---|---|---|
| 1 (start) | 0.8 mg | Pink/Red | $149 | 30 days |
| 2 | 2.5 mg | Yellow | $199 | 30 days |
| 3 | 5.5 mg | Green | $299 | 30 days |
| 4 | 9 mg | Pink/Red | $299 | 30 days |
| 5 | 14.5 mg | Yellow | $299* | 30 days |
| 6 (max) | 17.2 mg | Green | $299* | Maintenance |
*$299 if refilled within 45 days. $349 if the refill window is missed.
Now here is the part that deserves your attention. If you miss seven consecutive days, you restart the entire titration from 0.8 mg. Five months of progress, gone. With a weekly injection, missing a day or two is a non-event. You take your shot a couple days late and move on. With a daily pill, one bad week on vacation where you forgot your bottle and you are back to square one.
My standard advice applies here. If you are losing half a pound to three pounds per week at any dose, stay there. You do not need to chase the maximum. Every dose is a potential maintenance dose. Save the increases for when you actually need them.
What Foundayo Costs at Every Dose
Cost scales with dose. Self-pay pricing through LillyDirect: 0.8 mg is $149 a month. 2.5 mg is $199. At 5.5 and 9 mg, you are at $299. The top two doses (14.5 and 17.2 mg) are also $299, but only if you refill within 45 days. Miss that window and the price jumps to $349.
With commercial insurance and the Lilly savings card, you could pay as low as $25 a month at any dose. Medicare Part D coverage is expected starting July 1, 2026 at around $50 a month.
For context: Zepbound and Wegovy list at over $1,000 a month without insurance. Even at $349, Foundayo is a fraction of that. And you eliminate the cost of injection supplies, sharps containers, and refrigeration. No cold chain. Ships at room temperature like any other medication.
Insurance formulary updates for Foundayo are rolling out through Q3 2026. If your plan does not cover it yet, ask. That may change in the next few months.
Foundayo vs. the Wegovy Pill
There are now two GLP-1 pills on the market. They are not the same.
The Wegovy pill is semaglutide, the exact same molecule as the injection, reformulated for oral delivery. It works. The weight loss is comparable to the shot (around 17%). But it has rules: take it in the morning on an empty stomach with a small sip of water. Wait 30 minutes. Nothing else in your stomach.
Foundayo has no rules. Any time. Any meal. Any drink. But the weight loss is lower (around 12%).
| Feature | Foundayo (orforglipron) | Wegovy Pill (semaglutide) |
|---|---|---|
| Molecule type | Small molecule (non-peptide) | Peptide |
| Avg weight loss | ~12% | ~17% |
| Dosing frequency | Once daily, any time | Once daily, morning only |
| Food restrictions | None | Empty stomach, 30-min fast |
| Water restrictions | None | Small sip only |
| Starting price (self-pay) | $149/month | $149/month |
| Max dose price (self-pay) | $299-349/month | $299/month |
| Refrigeration | No | No |
So the trade-off is real. Maximum weight loss with a dosing ritual, or solid weight loss with zero friction.
For some patients, the convenience of Foundayo means they actually take it every day. And a pill you take every day beats a pill you skip because the fasting window did not fit your morning.
One note: no head-to-head trial of Foundayo vs. the Wegovy pill in obesity has been published. Novo Nordisk has referenced unreleased data claiming the Wegovy pill produces greater weight loss. In the ACHIEVE-3 trial (type 2 diabetes, not obesity), orforglipron 36 mg showed superior A1C reduction and weight loss versus oral semaglutide 14 mg. We will need the full obesity head-to-head data before drawing firm conclusions.
Foundayo Side Effects (What Surprised Me)
The side effect profile is what you would expect from a GLP-1. Nausea hit 36% of patients. Constipation 30%. Diarrhea 27%. These are class effects. The delivery method changed. The biology did not. If you are picturing the pill as the gentle version of GLP-1 therapy, these numbers should reset that expectation.
What stood out: the discontinuation rate at the highest dose was 10.3%, compared to 2.7% on placebo. That is higher than what we typically see with injectable GLP-1s. The best medication in the world does not work if people stop taking it.
Hair loss made the official common side effects list, reported at 4 to 5% versus about 2.4% on placebo. This is likely telogen effluvium (temporary shedding triggered by rapid weight loss and caloric deficit) rather than a direct drug effect. Adequate protein intake and avoiding overly restrictive eating help reduce this risk.
The upper GI symptoms (burping, acid reflux, flatulence) all hit the 5% threshold. Those likely reflect the pill hitting the stomach directly rather than bypassing it via injection.
Foundayo carries the same boxed warning as every other GLP-1: potential risk of thyroid C-cell tumors. Same class, same warning. If you or a family member has a history of medullary thyroid cancer or MEN2, this medication is not for you.
Drug interactions deserve a mention. Like all GLP-1s, Foundayo slows gastric emptying, which can affect absorption of other oral medications. But because it is a small molecule metabolized through the CYP3A4 pathway, it has additional interaction considerations with simvastatin, clarithromycin, carbamazepine, and cyclosporine. Your prescriber should review your full medication list before starting.
The Birth Control Warning
This one matters. The Foundayo label states that it can reduce absorption of oral birth control pills. The recommendation: use a backup method or switch to a non-oral contraceptive for 30 days after starting and 30 days after each dose increase.
Count that up. Six dose strengths. Six potential 30-day backup windows. If you are on oral birth control and you titrate all the way to the top, that is six months of needing backup contraception.
The simplest fix: an IUD, implant, patch, or ring. Non-oral methods are unaffected by any GLP-1. If you are a woman of reproductive age starting Foundayo, have this conversation with your prescriber before you fill the first prescription.
Who Should Consider Foundayo
Four types of patients where Foundayo makes clinical sense.
One: the needle was the barrier. You have been avoiding GLP-1 treatment entirely because of the injection. You knew you qualified. You knew the data. But the needle stopped you. That barrier is gone.
Two: you are in maintenance. You are at or near your goal weight on an injectable, and you want to transition from a weekly shot to a daily pill for long-term convenience. The ATTAIN-MAINTAIN data supports this approach, especially for patients coming off semaglutide.
Three: cost or access is a problem. You are on injectable semaglutide and doing well, but affordability is limiting your ability to stay on treatment. Foundayo is cheaper out of pocket at every dose level.
Four: you travel constantly. Refrigeration requirements, injection supplies, sharps disposal, and TSA conversations are a genuine hassle. Foundayo ships at room temperature and fits in your pocket.
The Switching Data (ATTAIN-MAINTAIN)
Lilly ran a study specifically designed to answer the switching question. The ATTAIN-MAINTAIN trial took 376 patients who had already lost weight on injectable Wegovy or Zepbound for 72 weeks (in the SURMOUNT-5 trial) and randomized them to oral Foundayo or placebo for another 52 weeks.
From Wegovy: patients maintained all but about 2 pounds of their prior weight loss. That is near-total preservation. From Zepbound: about 11 pounds of regain on average. Still meaningful maintenance, but a real difference that reflects the stronger effect of dual-receptor agonism.
In the study, patients did not start at 0.8 mg and climb the full ladder. They started at 12 mg and titrated up every 4 weeks to their maximum tolerated dose. Their GLP-1 receptors were already conditioned from over a year on injectables.
In this Foundayo review, the question I keep coming back to is this. If you are on Zepbound and you want to switch, what is the exact timing? Do you take your last injection on Sunday and start the pill on Monday? A week later? The detailed methods from that trial have not been published yet. When they are, I will update this post. Until then, your prescriber makes that call based on their clinical judgment and your individual situation.
Who Should Not Switch
No Foundayo review would be complete without saying this plainly. If you are on tirzepatide or semaglutide and you are losing steadily, your side effects are manageable, and your injection does not bother you, there is no clinical reason to switch to a less effective medication for the sake of novelty.
Foundayo is a tool. It is the right tool for certain patients. It is not an upgrade for everyone.
What I Am Doing Personally
I take tirzepatide. I lost 80 pounds on it. I am maintaining on it. My side effects are minimal. My injection takes 10 seconds a week.
I am not switching to Foundayo. For me, the math does not work. I am on a dual-receptor agonist that produces superior weight loss, and I have zero issue with the needle.
But I will be prescribing Foundayo to patients for whom it is the right fit. That list I just gave you? Those are real conversations I am already having in clinic.
That is my honest Foundayo review.
If you want help figuring out whether Foundayo, an injectable, or something else entirely is the right move for you, book a free consultation at barrickhealth.com.
Clete
Dr. Clete Barrick is a board-certified internal medicine and obesity medicine physician and the founder of Barrick Health, a telehealth and concierge medicine practice specializing in medical weight loss, peptide therapy, and comprehensive health optimization.
This content is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment. If you would like personalized guidance, you can book a free consultation with Dr. Barrick.
References
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18). DOI: 10.1056/NEJMoa2511774
- U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026.
- Eli Lilly and Company. Foundayo (orforglipron) tablets, for oral use. Prescribing Information. 2026.
- Ma X, Liu R, Pratt EJ, et al. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Orforglipron. Diabetes Ther. 2024;15(4):819-832.
- Eli Lilly and Company. ATTAIN-MAINTAIN topline results. Press release. December 18, 2025.
- Rosenstock J, Manghi FP, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. February 2026.
- Eli Lilly and Company. FDA approves Foundayo (orforglipron). Press release. April 1, 2026.